Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21764713 | 0.88 | CYP3A4 (0.48) | ALDH1A1LPAR3LPAR1LPAR2CYP3A4 | |
| SCHEMBL21764589 | 0.86 | LPAR3 (0.50) | ALDH1A1LPAR3LPAR1LPAR2CYP3A4 | |
| SCHEMBL21764796 | 0.85 | LPAR3 (0.53) | ALDH1A1LPAR3LPAR1LPAR2CYP3A4 | |
| SCHEMBL6671116 | 0.79 | CYP3A4 (0.42) | MEN1KMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL21764738 | 0.79 | MEN1 (0.33) | ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL28478944 | 0.77 | CYP3A4 (0.40) | MEN1KMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL21764565 | 0.77 | LPAR3 (0.38) | ALDH1A1MEN1KMT2ALPAR3LPAR1 | |
| SCHEMBL21764722 | 0.73 | TSHR (0.35) | ALDH1A1MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL28743332 | 0.73 | TSHR (0.46) | ALDH1A1MEN1KMT2ACYP3A4LMNA | |
| SCHEMBL27274519 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474860-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | AEQUOR INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | ALDH1A1 3876/4885MEN1 794/4885KMT2A 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.